Competitive Intelligence (CI)

Key facts

Typical scope

Competitor pipelines, launches, pricing, promotion, contracting and deals

Common public sources

ClinicalTrials.gov, Drugs@FDA, SEC filings, patents, congress abstracts

Trade secret laws

Economic Espionage Act of 1996; Defend Trade Secrets Act of 2016

What is competitive intelligence?

Competitive intelligence turns scattered information about rivals into answers a decision maker can act on: when a competitor's drug is likely to be approved, what its label may say, how it may be priced and how it could change the market. In life sciences, CI teams usually sit within strategy, commercial or portfolio functions.

CI differs from market research. Market research asks customers about their needs and preferences; competitive intelligence focuses on what competitors are doing and are likely to do next.

Where pharmaceutical CI comes from

Much of the raw material is public:

• ClinicalTrials.gov registrations and results, for competitor trial designs, endpoints, enrollment and timelines.
• FDA sources: Drugs@FDA approval documents, labels, advisory committee materials, the Orange Book and the Purple Book.
• Company disclosures: SEC filings, earnings calls and press releases, which often state expected FDA decision dates.
• Scientific congress presentations and journal publications for new data.
• Patent filings, litigation records and Paragraph IV challenges for loss of exclusivity timing.
• CMS data such as Medicare Part D prescriber files for uptake, and Open Payments records of competitor engagement with experts.

Why competitive intelligence matters

CI shapes launch timing, trial design, positioning and pricing. Knowing that a competitor's phase 3 trial is enrolling slowly, or that it excludes a patient subgroup, can change a brand's investment and messaging decisions.

Business development and investment teams use CI to value assets and anticipate crowded markets. Market access teams use it to prepare for payer contracting pressure when a competitor enters a class.

Ethical and legal limits of CI

CI must rely on public or lawfully obtained information. Misrepresenting identity to gather information, soliciting confidential data from a competitor's current or former employees, or acquiring trade secrets can violate the Economic Espionage Act of 1996, the Defend Trade Secrets Act of 2016 and company codes of conduct. Exchanging information directly with competitors about prices or strategy raises antitrust risk.